Navigation Links
Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Date:6/12/2013

BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the United Kingdom) prescribe carbapenems, especially meropenem (Cubist/AstraZeneca's Merrem/Meronem; Dainippon Sumitomo's Meropen; generics) and imipenem/cilastatin (Merck's Primaxin/Tienam; generics), as first- or second-line therapy for Gram-negative infections (GNIs) due to ESBL-producing Enterobacteriaceae. Such early-line use of these agents is indicative of the wider prescribing practices that fuel drug resistance and that have led to higher prevalence of carbapenem-resistant Gram-negative pathogens (GNPs), such as KPC-producing Enterobacteriaceae.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Drug-Resistant Gram-Negative Infections: How Will the Threat of Multidrug-Resistant Gram-Negative Pathogens Impact Market Access for Current and Emerging Antibiotics in the EU5? finds that nearly a third of surveyed physicians prescribe combinations of tigecycline (Pfizer's Tygacil), piperacillin/tazobactam (Pfizer's Zosyn/Tazocin; generics), carbapenems, aminoglycosides and polymyxins early in the treatment algorithm for infections due to multi-drug-resistant (MDR) GNPs, like KPC-producing Enterobacteriaceae or MDR-Pseudomonas. Reflective of physician concern over growing prevalence of these MDR pathogens and limited treatment options currently, over three-quarters of those surveyed anticipate prescribing emerging beta-lactam/beta-lactamase inhibitors CAZ-AVI (Forest/AstraZeneca) and CXA-201 (Cubist), primarily as a carbapenem-sparing therapy and as step therapy for patients failing anti-pseudomonal cephalosporin treatment, respectively.

The report also finds that economic hardships in Europe have translated to increasingly constrained hospital budgets. While the most expensive antibiotics are still cheap compared with biologics used in other therapy areas, interviewed payers warn that increasing patient numbers amid tightening budgets may result in insufficient diagnosis-related group reimbursement rates for overall treatment costs of GNIs, thereby forcing careful budget balancing in busy public institutions. Under pressure to optimize hospital and regional formularies by providing a diverse but cost-effective selection of antibiotics, these payers report that evidence of geographically tailored, cost-efficacy benefit is a key market access lever that will allow them to assess the benefits of novel premium-priced antibiotics against the backdrop of a highly genericized market.

"Interviewed Italian payers believe that even though hospitals are under pressure to reduce costs, they are eager for new therapies that effectively target drug-resistant Gram-negative pathogens," said Decision Resources Analyst Maria Ascano, Ph.D. "Novel therapies with such activity have the potential for rapid regional and hospital formulary inclusion; however manufacturers must be prepared for rigorous health technology assessments across the EU5, and must balance pricing expectations against potential uptake in this highly cost-constrained market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
2. Wound Management Products Market Reaches $15.2 Billion by 2016, Driven by Rising Demand for Bandages and Dressings in Developing World
3. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
4. BidOnHealth.com Offers a Solution to Rising Healthcare Costs
5. Independent Schools Consortium Slams Brakes on Rising Health Care Costs
6. Active Pharmaceutical Ingredients (API) Global Market to 2017 - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand
7. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
8. Polymers in Medical Devices: Opportunities Arising and Trends Impacting the Market
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
11. Rising Disease Prevalence Boosts Mexican Healthcare Industry, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Acidity Regulators Market - ... market for acidity regulators was valued at $4,456 million in 2015, ... a CAGR of 7.96% from 2016 to 2022. Asia-Pacific ... to maintain its lead, followed by North America ...
(Date:1/24/2017)... SAN FRANCISCO , January 24, 2017 ... reach a value of USD 3.8 billion by 2025, ... Inc. The market growth can be attributed to the ... awareness about early diagnosis of micro calcifications in breast ... Cancer Foundation, CDC, and Breast Cancer Organization are promoting ...
(Date:1/24/2017)... For today, Stock-Callers.com scans the following Biotechnology companies: ... Inc. (NASDAQ: ALDR ), BioDelivery Sciences International Inc. ... EGLT ). These equities are part of the Healthcare ... , 2017, with the NYSE Health Care Index dropping about ... 500 also were down 0.3% as a group. These stocks ...
Breaking Medicine Technology:
(Date:1/24/2017)... Milford, PA (PRWEB) , ... January 24, 2017 ... ... their main product “Lacto-Freedom” was recently accepted as a Registered Trademark by the ... prevent others from using a similar name which could confuse consumers into thinking ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by ... 12th year in 2017. The entrepreneurs will showcase their businesses on February 6, ...
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide ... a distribution partnership with Byers Scientific & Manufacturing , a leading designer, ... the agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The University of ... taken great care to design a program that provides teachers with the specific skills ... This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com is working to ...
Breaking Medicine News(10 mins):